1. Inicio
  2. Publicaciones
  3. Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis.TACRO-TOPIC study of GETECCU

Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis.TACRO-TOPIC study of GETECCU

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Fuentes-Valenzuela E.
  • Bastón-Rey I.
  • García-Alonso F.J.
  • Elosua A.
  • San Martín L.Z.
  • Carnerero E.L.
  • de la Filia I.G.
  • Pérez A.P.
  • Chumillas R.M.S.
  • Oliver A.P.
  • Villafranca C.M.
  • Moreno V.
  • Ferrer C.S.
  • Molina G.
  • Ferreiro-Iglesias R.
  • Villaamil P.V.
  • Mateos D.G.
  • Segarra-Ortega J.X.
  • Doallo A.I.
  • Alonso-Galán H.
  • Brunet-Mas E.
  • García N.J.
  • López Romero-Salazar F.
  • Velayos B.
  • Carballo-Folgoso L.
  • Santamaría C.P.
  • Román L.M.
  • Ortiz A.N.
  • Barrio J.
  • Acosta M.B.-D.
  • Gutiérrez-Casbas A.

Grupos

Abstract

Introduction: Data about the efficacy of topical therapy with tacrolimus in patients with ulcerative colitis (UC) are scarce. Therefore, this study aimed to evaluate topical tacrolimus’s (TT) effectiveness and adverse events in a real-world setting. Methods. A multicenter retrospective study was conducted at 27 hospitals across Spain. Adult patients with UC who had received suppositories, enemas, or tacrolimus ointment due to persistent clinical or endoscopic activity despite topical mesalamine and/or steroids from January 2009 to January 2023 were included. The primary outcome was clinical response at week 8. Results: A total of 148 patients were included. Sixty-nine patients (46.6%) received suppositories, 78 (52.7%) received enemas, and one patient used an ointment (0.7%). Clinical remission was achieved in 43 (33.6%), and clinical response in 76 (59.4%) patients at week 4. The primary outcome was achieved in 87 (67.4%), and clinical remission was achieved in 61 patients (47.3%) at week 8. Median tacrolimus trough level was 3.4 ng/mL (IQR 1.5-6.7) at week 4 and 2.9 ng/mL (IQR 1.5-6) at week 8. After a median follow-up of 55.1 weeks (IQR 40.6-55.7) since starting TT, 63 (42.6%) patients needed treatment escalation other than tacrolimus during the follow-up period, with a 1-year risk of treatment escalation of 46.2% (95% CI 37.3-56.1%). Adverse events were detected in 21 patients (14.2%), with 12 graded as mild and 9 as moderate (42.6%). Conclusions: Topical tacrolimus is an effective therapy and could be considered in distal UC patients before initiating other advanced therapies when endoscopic activity remains. © The Author(s) 2025. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
1873-9946, 1876-4479

Journal of Crohns & Colitis  OXFORD UNIV PRESS

Tipo:
Article
Páginas:
-
PubMed:
40205922
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
2,429 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Administration, Rectal; Adult; Colitis, Ulcerative; Enema; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Remission Induction; Retrospective Studies; Spain; Suppositories; Tacrolimus; Treatment Outcome; C reactive protein; calgranulin; corticosteroid; enema; immunomodulating agent; mercaptopurine; mesalazine; steroid; tacrolimus; enema; immunosuppressive agent; tacrolimus; adult; arthralgia; Article; cataract; drug efficacy; drug safety; drug withdrawal; endoscopy; female; hospitalization; human; immunosuppressive treatment; infection; major clinical study; male; mild renal impairment; multicenter study; neurologic disease; ointment; outcome assessment; rectum; retrospective study; skin irritation; subtotal colectomy; suppository; topical treatment; ulcerative colitis; ulcerative colitis endoscopic index of severity; clinical trial; drug therapy; middle aged; rectal drug administration; remission; Spain; treatment outcome; ulcerative colitis

Compartir